ClinicalTrials.gg
Status unknownNCT04406636SHIELD HDUpdated Sep 23, 2022

Natural History Study in Huntington Disease Gene Expansion Carriers (HDGECs) - SHIELD HD

An observational study in Huntington Disease, sponsored by CHDI Foundation, Inc.. Status unknown at 10 sites in 5 countries. Open to participants aged 18 Years to 63 Years. Per ClinicalTrials.gov, last updated 2022-09-23.

Sponsored by CHDI Foundation, Inc. · Observational

How we know

The sponsor has not verified this record recently (last verified Sep 2022), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
70
Ages
18 Years to 63 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Huntington Disease by CHDI Foundation, Inc. — 2 open to participants now, 2 under way, none of them phase 3. Huntington Disease · CHDI Foundation, Inc..

Started
2020
with 2 others
Observational
7 of 11
1 open now
Registered
10th of 11
by date

Among the 11 studies in Huntington Disease by CHDI Foundation, Inc., this one is one of 3 that started in 2020, is one of 7 observational ones, and was the 10th registered.

Huntington Disease

293 studies on the registry are indexed under Huntington Disease; 54 are open to participants now.

Browse Huntington Disease studies →

Open to participants now

2 of the 11 studies in Huntington Disease by CHDI Foundation, Inc. are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 43 Huntington Disease studies recruiting now, 19 (44%) set no upper age limit and 20 (47%) stop at 75 or younger; 5 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 63 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Huntington Disease by CHDI Foundation, Inc., or all of them as a file.
02

Study summary

SHIELD HD is an international, multisite, prospective, longitudinal cohort natural history study to assess the natural history of HD and its biomarkers that are associated with modulation of the number of cytosine-adenine-guanine (CAG) repeats in the mutant Huntingtin (HTT) gene.

Approximately 60 patients will be enrolled into the study and followed for up to 24 months at clinical sites in North America and Europe.

The results of this study will inform assessments for a future interventional treatment trial.

Read the detailed description

The rationale for this study is to obtain longitudinal information related to Somatic Instability and DNA damage response genes in HDGECs at various stages of the disease. Established assessments of disease progression will also be recorded.

03

Conditions studied

  • Huntington Disease

Browse trials for

Keywords

  • HD
04

Who can participate

Ages eligible
18 Years to 63 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Huntington disease (HD), genetically confirmed by direct DNA testing, either obtained previously or performed at Screening

Eligibility criteria

Key Inclusion Criteria

Patients who meet all of the following criteria will be eligible to participate in the study:

  1. Capacity to comprehend the study objectives and procedures
  2. Documentation of genetically confirmed disease by direct DNA testing, defined as a CAG repeat length ≥39 in the HTT gene
  3. Ability to undergo and tolerate MRI scans
  4. Ability to tolerate blood draws and lumbar punctures

Key Exclusion Criteria

Patients who meet any of the following criteria will be excluded from participation in the study:

  1. Any conditions, including severe chorea and dementia, that would prevent either writing or performing pen and paper, tablet, or computer based tasks as determined by the Investigator
  2. Treatment with an drug within 30 days prior to screening or within 5 half lives of the investigational drug, whichever is longer
  3. History of gene therapy or cell transplantation or any other experimental brain surgery
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
70 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. DDR gene expression

    To assess deoxyribonucleic acid (DNA) damage repair (DDR) gene expression in accessible biofluids and disease trajectories for established and novel biomarkers and clinical outcomes.

    Time frame: 2 years

Secondary outcomes

  1. Compare rates of change in biomarkers for disease progression

    To compare the rates of change for different outcomes and cytosine adenine guanine (CAG) age product (CAP) Scores.

    Time frame: 2 years

Other outcomes

  1. Additional biomarkers to be examined

    The exploratory objectives of this study are to be determined and may include the examination of additional biomarkers present in CSF, plasma, and whole blood, including but not limited to mutant HTT (mHTT) protein, cytokines, and others, as well as clinical markers of progression.

    Time frame: 2 years

07

Study locations

10 sites
  • University of California, San Diego (UCSD)
    San Diego, California 920161, United States
  • Rocky Mountain Movement Disorders Center
    Englewood, Colorado 80113, United States
  • Beth Israel Deaconess
    Boston, Massachusetts 02215, United States
  • Columbia University
    New York, New York 10032, United States
  • Inland Northwest Research
    Spokane, Washington 99202, United States
  • Centre for Movement Disorders
    Toronto, Ontario M3B 257, Canada
  • North York General Hospital
    Toronto, Ontario, Canada
  • ICM - Institut du Cerveau et de la Moelle épinière
    Paris, 75013, France
  • George-Huntington-Institut (GHI)
    Muenster, Germany
  • University College London - Institute of Neurology & The National Hospital for Neurology and Neurosurgery
    London, United Kingdom
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2020 (actual). Primary completion is estimated for Apr 2023, 35 months after the start.

Of 34 observational studies under Huntington Disease, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 34. This study's planned 35 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2020
First posted
May 28, 2020
StartActual
May 19, 2020
Primary completionEst.
Apr 2023
CompletionEst.
Apr 2023
Last update
Sep 23, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04406636
Lead sponsor
CHDI Foundation, Inc.
Collaborators
Medpace, Inc.
Responsible party
Sponsor
First posted
May 28, 2020
Start date
May 19, 2020
Primary completion
Apr 2023 (estimated)
Completion
Apr 2023 (estimated)
Last update
Sep 23, 2022

Study contacts

Anne Rosser, PhD FRCP
principal investigator · Cardiff University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion